熱門資訊> 正文
Cullinan Therapeutics GAAP每股收益为-0.75美元
2024-08-08 20:19
- Cullinan Therapeutics press release (NASDAQ:CGEM): Q2 GAAP EPS of -$0.75.
- Cash, cash equivalents, investments, and interest receivable were $664.9 million as of June 30, 2024.
-
More on Cullinan Therapeutics
- Checking Into Cullinan Therapeutics
- Seeking Alpha’s Quant Rating on Cullinan Therapeutics
- Historical earnings data for Cullinan Therapeutics
- Financial information for Cullinan Therapeutics
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。